Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.
Ticker SymbolBJDX
Company nameBluejay Diagnostics Inc
IPO dateNov 10, 2021
CEOMr. Neil (Indranil) Dey
Number of employees7
Security typeOrdinary Share
Fiscal year-endNov 10
Address360 Massachusetts Avenue, Suite 203
CityACTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code01720
Phone19786310152
Websitehttps://bluejaydx.com/
Ticker SymbolBJDX
IPO dateNov 10, 2021
CEOMr. Neil (Indranil) Dey
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data